Pain Induced by m-Cresol as Preservative

Pain Induced by m-Cresol as Preservative - A Randomised Controlled Crossover-Trial in Healthy Volunteers

Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth. However, clinical reports have suggested that these preservatives may cause local discomfort or pain at the injection site, which can negatively impact treatment adherence. While m-Cresol is widely used, its direct contribution to injection-site pain has not yet been investigated in a prospective clinical trial.

This study aims to investigate whether subcutaneous injection of m-Cresol at concentrations commonly used in clinical practice (0.1% and 0.25%) cause significantly more pain than a preservative-free control solution. In a randomized, double-blind crossover design, healthy volunteers will receive three separate injections in a belly fold. Participants will rate their pain every 5 seconds until it subsides. The findings will help determine if m-Cresol is a primary source of injection-site pain and could lead to the development of more comfortable drug formulations.

Study Overview

• Status: Not yet recruiting
• Conditions: Pain; Acute Pain; Healthy Volunteer Study
• Intervention / Treatment: Other: m-Cresol 0.1%; Other: m-Cresol 0.25%; Other: Control Solution

Detailed Description

Background and Objective:

m-Cresol has been used since 1980 to limit bacterial growth in parenteral medications. Although it is generally considered safe, evidence for local side effects has appeared in case reports and a clinical trial where changing the preservative led to a disappearance of local discomfort. This suggests that the preservative itself, rather than the active drug or the pH of the solution, may be responsible for a pain sensation. The objective of this study is to systematically evaluate if subcutaneous injection of m-Cresol at clinically relevant concentrations causes pain in humans.

Study Design:

This is a randomized, double-blind, placebo-controlled, 3-period crossover trial in healthy volunteers (n=18). To ensure an unbiased assessment and control for potential order effects, a Williams balanced design is utilized for the randomization of treatment sequences.

Methodology:

Familiarization: Participants first receive an unblinded injection of control solution to become accustomed to the experimental procedure and the numerical pain rating scale.

Interventions: Subjects receive three randomized, double-blind 300 µl subcutaneous injections at different spots on a belly fold, separated by at least 3 cm. The treatments include:

1. m-Cresol at 0.1%
2. m-Cresol at 0.25%
3. Control solution. Pain Assessment: For each injection, pain intensity is recorded every 5 seconds using a numerical pain rating scale (0-100) until no pain is reported for 30 consecutive seconds. The pain caused by the needle insertion itself is rated separately before the injection begins to serve as a covariate for the statistical analysis.

Statistical Analysis:

The primary endpoint is the Area Under the Curve (AUC) of the subjective pain ratings over time. Comparisons will be made between the different m-Cresol concentrations and the vehicle control using a linear mixed model to test the primary hypotheses.

• Study Type: Interventional
• Enrollment (Estimated): 18
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Felix J. Resch; Phone Number: +43 1 40160 31419; Email: felix.resch@meduniwien.ac.at
• Study Contact Backup: Name: Michael J.M. Fischer; Phone Number: +43 1 40160 31410; Email: michael.jm.fischer@meduniwien.ac.at

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion criteria

• Age between 18 and 70 years
• Full legal capacity Exclusion criteria
• Participant of another study, ongoing or within the last four weeks
• Current medication intake (except hormonal contraception) or drug abuse
• Female subjects: Positive pregnancy test or breastfeeding
• Body temperature above 38°C, verified by infrared thermometer
• Known allergic diseases, in particular asthmatic disorders and skin diseases
• Sensory deficit, skin disease or hematoma of unknown origin in the examination of the test site

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: m-Cresol 0.1%; Participants receive a 300 µl subcutaneous injection of m-Cresol at a concentration of 0.1%.	Other: m-Cresol 0.1%; A preservative administered subcutaneously at 0.1%, a common concentration used in medicines.
Experimental: m-Cresol 0.25%; Participants receive a 300 µl subcutaneous injection of m-Cresol at a concentration of 0.25%.	Other: m-Cresol 0.25%; A preservative administered subcutaneously at 0.25%, a common concentration used in medicines.
Placebo Comparator: Control solution; Participants receive a 300 µl subcutaneous injection of control solution.	Other: Control Solution; A control solution administered subcutaneously.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Curve (AUC) of Pain Intensity	Total pain burden calculated as the Area Under the Curve of serial pain ratings (0-100 numerical pain rating scale) recorded every 5 seconds from the start of injection until no pain is reported for 30 seconds.	From injection start until pain subsides (approximately 15-60 seconds per injection).

Collaborators and Investigators

• Sponsor: Medical University of Vienna
• Investigators: Principal Investigator: Michael J.M. Fischer, Medical University of Vienna

Study record dates

Study Major Dates

• Study Start (Estimated): May 25, 2026
• Primary Completion (Estimated): June 8, 2026
• Study Completion (Estimated): June 8, 2026

Study Registration Dates

• First Submitted: May 15, 2026
• First Submitted That Met QC Criteria: May 15, 2026
• First Posted (Actual): May 22, 2026

Study Record Updates

• Last Update Posted (Actual): May 22, 2026
• Last Update Submitted That Met QC Criteria: May 15, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Nociception; Subcutaneous Injection; Preservative; Experimental Pain Models; Human Pain Models; m-Cresol
• Additional Relevant MeSH Terms: Neurologic Manifestations; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Pain; Acute Pain
• Other Study ID Numbers: EK1688/2024

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual participant data (IPD), including pain ratings, time-stamped injection responses, and basic demographics (age, sex), will be shared alongside the publication of the primary results. Only data used in the main publication and relevant supplementary analyses will be included.
• IPD Sharing Time Frame: IPD will be made available at the time of publication of the primary resultsarticle, as a supplementary file.
• IPD Sharing Access Criteria: All individuals who have access to the published article will be able to access the individual participant data (IPD) and supporting information as supplementary material. No special request or data use agreement is required.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No